Manufacturing, latest filing in 2025

Aardvark Therapeutics, Inc. IPO

Aardvark Therapeutics, Inc. filed a Form S-1 registration statement for an initial public offering on 2025-01-23. It has amended it 1 time. It filed its final prospectus on 2025-02-13, at a public offering price of $16.00 per share. Each fact below is quoted from the filing named with it.

Swipe the table sideways to see every column.

Our common stock has been approved for listing on the Nasdaq Global Select Market (Nasdaq) under the symbol “AARD.”From the 424B4 filed 2025-02-13

The initial public offering price is $16.00 per share.From the 424B4 filed 2025-02-13

We currently intend to use the net proceeds to us from this offering, together with our existing cash, cash equivalents and short-term investments, to advance the clinical development of ARD-101, to advance the clinical development of ARD-201, to fund expenses associated with our other clinical and preclinical programs and other research and development activities, and for working capital, operating expenses, capital expenditures and other general corporate purposes.From the 424B4 filed 2025-02-13

For the years ended December 31, 2022 and 2023, we reported a net loss of $13.6 million and $7.2 million, respectively, and for the nine months ended September 30, 2023 and 2024, we reported a net loss of $5.2 millionFrom the S-1/A filed 2025-02-06

Swipe the table sideways to see every column.

AIRO Group Holdings, Inc. IPO

AIRO Group Holdings, Inc. filed a Form S-1 registration statement for an initial public offering on 2025-02-21. It has amended it 2 times. It filed its final prospectus on 2025-09-12. Each fact below is quoted from the filing named with it.

Swipe the table sideways to see every column.

Our common stock is listed on the Nasdaq Global Market (“Nasdaq”) under the symbol “AIRO.” On September 10, 2025, the last reported sale price of our common stock on Nasdaq was $19.42 per share.From the 424B4 filed 2025-09-12

We are offering 4,200,000 shares of our common stock, par value $0.000001 per share.From the 424B4 filed 2025-09-12

We currently expect that the initial public offering price will be between $14.00 and $16.00 per share of our common stock.From the S-1/A filed 2025-05-20

We currently intend to use the net proceeds from this offering as follows:From the 424B4 filed 2025-06-16

We have incurred significant net losses since inception, with the exception of the six months of June 30, 2025, during which we reported net income of $3.9 million.From the S-1 filed 2025-09-08

Swipe the table sideways to see every column.

Anbio Biotechnology IPO

Anbio Biotechnology filed a Form F-1 registration statement for an initial public offering on 2024-12-31. It has amended it 3 times. It filed its final prospectus on 2025-02-19. Each fact below is quoted from the filing named with it.

Our Class A Ordinary Shares have been approved for listing on Nasdaq Global Market under the symbol “NNNN”.From the 424B4 filed 2025-02-19

We are offering 1,600,000 Class A ordinary shares, par value US$0.0001 per share (the “Class A Ordinary Shares”), of Anbio Biotechnology (“Anbio”, the “Company”, “we”, “our”, “us”), a Cayman Islands exempted company.From the 424B4 filed 2025-02-19

We intend to use the net proceeds of this offering primarily for expansion of sales and distribution network in the strategically selected markets, research and development, and working capital and general corporate matters.From the 424B4 filed 2025-02-19

For the six months ended June 30, 2024 and 2023, we generated revenue of $5.85 million and $3.06 million, respectively, of which 44% and 99% were from respiratory diseases and COVID -19 related products.From the F-1/A filed 2025-01-10

We generated a net income of $2,253,709 for the year ended December 31, 2023, as compared to $10,011,177 for the year ended December 31, 2022, a decrease of $7,757,468 or approximately 77.5%, predominately due to reasons as discussed above.From the F-1/A filed 2025-01-10

Swipe the table sideways to see every column.

Aoje Inc. IPO

Aoje Inc. filed a Form F-1 registration statement for an initial public offering on 2025-12-23. As of its latest filing, on 2025-12-23, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.

We have reserved the symbol “AOJE” for purposes of listing the Class A Ordinary Shares on the Nasdaq Stock Market LLC (“Nasdaq”) and have applied to list the Class A Ordinary Shares on the Nasdaq Capital Market.From the F-1 filed 2025-12-23

Swipe the table sideways to see every column.

Ascentage Pharma Group International IPO

Ascentage Pharma Group International filed a Form F-1 registration statement for an initial public offering on 2024-12-27. It has amended it 1 time. It filed its final prospectus on 2025-01-24. Each fact below is quoted from the filing named with it.

The ADSs have been approved for listing on the Nasdaq Global Market, or Nasdaq, under the symbol “AAPG.” Application will be made to the HKEx for the listing of the ordinary shares represented by the ADSs we are offering, and we expect to obtain the approval of the HKEx before the ordinary shares are issued upon the closing of the offering.From the 424B4 filed 2025-01-24

We intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, as follows:From the 424B4 filed 2025-01-24

For the nine months ended September 30, 2024, we generated revenue of RMB876.8 million (US$124.9 million) from intellectual property income, sales of pharmaceutical products and commercialization rights income, compared to RMB175.5 million for the nine months ended September 30, 2023, representing an increase of RMB701.3 million, or 400.0%, which was primarily attributable to intellectual property income of RMB678.4 million from Takeda and the increase in sales of pharmaceuticals products of RMB11.9 million.From the F-1/A filed 2025-01-21

While our net profit was RMB162.8 million (US$22.4 million) for the six months ended June 30, 2024, our net loss was RMB402.3 million for the six months ended June 30, 2023, and we incurred a net loss of RMB925.7 million (US$127.4 million) and RMB882.9 million for the years ended December 31, 2023 and 2022, respectively.From the F-1/A filed 2025-01-21

Swipe the table sideways to see every column.

Aurion Biotech, Inc. IPO

Aurion Biotech, Inc. filed a Form S-1 registration statement for an initial public offering on 2025-01-24. It asked for the registration statement to be withdrawn on 2025-05-23. Each fact below is quoted from the filing named with it.

We have applied to list our common stock on the New York Stock Exchange under the symbol “AURN,” and this offering is contingent upon obtaining such approval.From the S-1 filed 2025-01-24

We intend to use the net proceeds from this offering for the following purposes:From the S-1 filed 2025-01-24

Our net losses were $47.7 million and $33.4 million for the nine months ended September 30, 2024 and 2023, respectively, and $45.5 million and $35.7 million for the years ended December 31, 2023 and 2022, respectively.From the S-1 filed 2025-01-24

Aurion Biotech, Inc. (the “ Company ”), hereby requests, pursuant to Rule 477 of the Securities Act of 1933, as amended (“ Securities Act ”), that the Company’s Registration Statement on Form S-1 (File No. 333-284471), initially filed with the Securities and Exchange Commission (“ SEC ”) on January 24, 2025, together with all exhibits and amendments thereto (collectively, the “ Registration Statement ”), be withdrawn effective immediately.From the RW filed 2025-05-23

Swipe the table sideways to see every column.

BETA Technologies, Inc. IPO

BETA Technologies, Inc. filed a Form S-1 registration statement for an initial public offering on 2025-09-29. It has amended it 2 times. It filed its final prospectus on 2025-11-04. Each fact below is quoted from the filing named with it.

Swipe the table sideways to see every column.

We have been approved to list our Class A common stock on the New York Stock Exchange (“NYSE”) under the symbol “BETA.”From the 424B4 filed 2025-11-04

This is the initial public offering of Class A common stock of BETA Technologies, Inc. We are offering 29,852,941 shares of our Class A common stock, par value $0.0001 per share (the “Class A common stock”).From the 424B4 filed 2025-11-04

The estimated initial public offering price of our Class A common stock is between $27.00 and $33.00 per share.From the S-1/A filed 2025-10-15

We intend to use the net proceeds from this offering primarily for general corporate purposes.From the S-1 filed 2025-09-29

Our revenues were $15.4 million for the year ended December 31, 2023, $15.1 million for the year ended December 31, 2024 and $15.6 million for the six months ended June 30, 2025.From the S-1/A filed 2025-10-15

We incurred net losses of $175.6 million and $275.6 million for the years ended December 31, 2023 and 2024, respectively.From the S-1/A filed 2025-10-15

Swipe the table sideways to see every column.

Bialgo Commercial Operation Management CO., Ltd IPO

Bialgo Commercial Operation Management CO., Ltd filed a Form F-1 registration statement for an initial public offering on 2025-01-28. As of its latest filing, on 2025-01-28, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.

We have reserved the trading symbol BGO for listing on the NASDAQ.From the F-1 filed 2025-01-28

We intend to use the net proceeds of this offering:From the F-1 filed 2025-01-28

Swipe the table sideways to see every column.

BrilliA Inc IPO

BrilliA Inc filed a Form F-1 registration statement for an initial public offering on 2024-09-12. It has amended it 4 times. It filed its final prospectus on 2024-11-27, at a public offering price of $4.00 per share. Each fact below is quoted from the filing named with it.

We have received approval to list our Class A Shares on the NYSE American under the symbol “BRIA”.From the 424B4 filed 2024-11-27

We are offering, on a firm commitment engagement basis, 2,500,000 Class A Shares.From the 424B4 filed 2024-11-27

____________ (1) Each $1.00 increase in the initial public offering price of $4.00 per share, would increase the pro forma as adjusted amount of each of additional paid -in capital and total capitalization by approximately $2.3 million, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.From the 424B4 filed 2024-11-27

We currently intend to use the net proceeds from this offering (i) capital expenditure on developing digital marketing platform, (ii) capital expenditure on opening retail outlets, (iii) marketing expenses; and (iv) for general working capital and corporate purposes.From the 424B4 filed 2024-11-27

Swipe the table sideways to see every column.

Charming Wow Inc IPO

Charming Wow Inc filed a Form F-1 registration statement for an initial public offering on 2025-07-31. As of its latest filing, on 2025-07-31, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.

We intend to apply to list our common stock on the Nasdaq Capital Market under the symbol “YMXK”.From the F-1 filed 2025-07-31

Swipe the table sideways to see every column.

China Tobacco & Alcohol Group Ltd IPO

China Tobacco & Alcohol Group Ltd filed a Form F-1 registration statement for an initial public offering on 2025-08-06. As of its latest filing, on 2025-08-06, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.

We have applied to list our common stock on the Nasdaq Capital Market under the symbol “ZY”.From the F-1 filed 2025-08-06

We are offering 4,000,000 ordinary shares of the Company pursuant to this Offering.From the F-1 filed 2025-08-06

Swipe the table sideways to see every column.

COR3&Co. (Holdings) Ltd IPO

COR3&Co. (Holdings) Ltd has a Form F-1 registration statement on file for an initial public offering; the original was filed before the period this page covers, and the earliest filing here is an amendment filed on 2024-10-17. Amendments on record here: 6. It asked for the registration statement to be withdrawn on 2025-07-18. Each fact below is quoted from the filing named with it.

We intend to list our Ordinary Shares on Nasdaq under the symbol “COC”.From the F-1/A filed 2025-05-21

We are offering, on a firm commitment engagement basis, 2,250,000 Ordinary Shares.From the F-1/A filed 2025-05-21

We currently intend to use the net proceeds from this offering (i) for online expansion of our retail network;From the F-1/A filed 2025-05-21

Pursuant to Rule 477 under the Securities Act, we hereby submit this letter to notify the Commission of the withdrawal of the Registration Statement because the Company does not intend to pursue the contemplated public offering of the securities covered by the Registration Statement at this time.From the RW filed 2025-07-18

Swipe the table sideways to see every column.

Cre8 Enterprise Ltd IPO

Cre8 Enterprise Ltd filed a Form F-1 registration statement for an initial public offering on 2024-08-19. It has amended it 8 times. It filed its final prospectus on 2025-07-23. Each fact below is quoted from the filing named with it.

Swipe the table sideways to see every column.

Our Class A Ordinary Shares have been approved for listing on the Nasdaq Capital Market under the symbol “CRE”.From the 424B4 filed 2025-07-23

We are offering 1,450,000 Class A Ordinary Shares, representing 7.46% of the Class A Ordinary Shares issued and outstanding following completion of the Offering, assuming the underwriter do not exercise the over -allotment option.From the 424B4 filed 2025-07-23

Swipe the table sideways to see every column.

Curanex Pharmaceuticals Inc IPO

Curanex Pharmaceuticals Inc filed a Form S-1 registration statement for an initial public offering on 2024-10-16. It has amended it 6 times. It filed its final prospectus on 2025-08-26, at a public offering price of $4.00 per share. Each fact below is quoted from the filing named with it.

Our Common Stock was approved for listing on the Nasdaq Capital Market (“Nasdaq”) under the symbol “CURX.”From the 424B4 filed 2025-08-26

Negotiations with the Underwriters determined the initial public offering price of $4.00 per share in the IPO, which may bear no relationship to the market price of our shares of Common Stock after the IPO. the Underwriters and may not be indicative of prices that will prevail in the open market following this Offering.From the 424B4 filed 2025-08-26

We intend to use the net proceeds received from this underwritten offering for general and working capital purposes, including but not limited to investing in research and development, including in our technology, and for other working capital and general corporate purposes.From the 424B4 filed 2025-08-26

As a result of the factors mentioned above, we reported a net loss of $224,343 for the nine months ended September 30, 2024, compared to a net loss of $6,527 for the nine months ended September 30, 2023.From the S-1/A filed 2024-11-27

Swipe the table sideways to see every column.

Earntz Healthcare Products, Inc. IPO

Earntz Healthcare Products, Inc. has a Form F-1 registration statement on file for an initial public offering; the original was filed before the period this page covers, and the earliest filing here is an amendment filed on 2024-09-16. Amendments on record here: 1. It asked for the registration statement to be withdrawn on 2025-08-15. Each fact below is quoted from the filing named with it.

We have reserved the trading symbol ETZ for listing on the NASDAQ.From the F-1/A filed 2024-09-16

We are offering on a firm commitment basis 2,500,000 ordinary shares.From the F-1/A filed 2024-09-16

Our total revenue decreased by approximately $1.5 million, or 16%, from approximately $9.7 million for the year ended December 31, 2022 to approximately $8.2 million for the year ended December 31, 2023.From the F-1/A filed 2024-09-16

Our net loss increased by approximately $2.6 million, or 213%, from approximately $1.2 million for the year ended December 31, 2022 to a net loss of approximately $3.9 million for the year ended December 31, 2023.From the F-1/A filed 2024-09-16

Pursuant to Rule 477 under the Securities Act of 1933, as amended (the “ Securities Act ”), Earntz Healthcare Products, Inc., a foreign private issuer organized under the laws of Cayman Islands (the “ Company ”), hereby respectfully requests that the Securities and Exchange Commission (the “ Commission ”) consent to the withdrawal of its Registration Statement on Form F-1 (File No. 333- 269806) together with all exhibits thereto (the “ Registration Statement ”), effective as of the date hereof or at the earliest practicable date hereafter.From the RW filed 2025-08-15

Swipe the table sideways to see every column.

Everfront Biotech Holding Co Ltd IPO

Everfront Biotech Holding Co Ltd filed a Form F-1 registration statement for an initial public offering on 2025-01-03. It has amended it 2 times. As of its latest filing, on 2025-12-11, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.

We have reserved the symbol “ EFB ” for the purpose of listing our Ordinary Shares on the Nasdaq Capital Market (“Nasdaq”).From the F-1/A filed 2025-12-11

We plan to use the net proceeds we receive from this offering for the following purposes.From the F-1/A filed 2025-12-11

Therefore, we generated no revenue from product sales in the year ended December 31, 2023, and the revenue of $79,908 recorded in the year ended December 31, 2022 was the service revenue from the fibroblast culture process research commissioned by the related party Xi Yue Biomedicine Inc. (formerly Guang-Li Biomedicine Inc.).From the F-1 filed 2025-01-03

The Company has suffered net losses of $581,938 and $787,712 for the six months ended June 30, 2025 and 2024, respectively, and used net cash in operating activities of $681,394 and $785,070 for the six months ended June 30, 2025 and 2024, respectively, and has an accumulated deficit of $22,378,190 as of June 30, 2025.From the F-1/A filed 2025-12-11

Swipe the table sideways to see every column.

Flowco Holdings Inc. IPO

Flowco Holdings Inc. filed a Form S-1 registration statement for an initial public offering on 2024-12-06. It has amended it 4 times. It filed its final prospectus on 2025-01-16. Each fact below is quoted from the filing named with it.

Swipe the table sideways to see every column.

The newest 12 of 22 records.

We have been approved to list our Class A common stock on The New York Stock Exchange (the “NYSE”) under the symbol “FLOC.”From the 424B4 filed 2025-01-16

This is an initial public offering of shares of Class A common stock of Flowco Holdings Inc. We are selling 17,800,000 shares of Class A common stock.From the 424B4 filed 2025-01-16

We intend to use the net proceeds from this offering to acquire LLC Interests of Flowco LLC, and Flowco LLC intends to use such proceeds to:From the 424B4 filed 2025-01-16

Swipe the table sideways to see every column.

Fuxing China Group Ltd IPO

Fuxing China Group Ltd has a Form F-1 registration statement on file for an initial public offering; the original was filed before the period this page covers, and the earliest filing here is an amendment filed on 2024-08-21. Amendments on record here: 8. It asked for the registration statement to be withdrawn on 2025-12-09. Each fact below is quoted from the filing named with it.

We have reserved the symbol “FFFZ” for purposes of listing the ADSs on the Nasdaq Capital Market (“Nasdaq”) and have applied to list the ADSs on Nasdaq.From the F-1/A filed 2025-02-27

We are offering a total of 1,500,000 ADSs.From the F-1/A filed 2025-02-27

Our total revenue decreased from approximately US$54.4 million for the six months ended September 30, 2023 to approximately US$51.2 million for the six months ended September 30, 2024.From the F-1/A filed 2025-02-27

Pursuant to Rule 477 under the Securities Act of 1933 (the “Act”), Fuxing China Group Limited (the “Company”) respectfully requests the immediate withdrawal of its Registration Statement on Form F-1 (File No. 333-278459) initially filed with the Securities and Exchange Commission (the “Commission”) on April 2, 2024, together with all exhibits, and amendments thereto (the “Registration Statement”), with such application to be approved effective as of the date hereof or at the earliest practical date thereafter.From the RW filed 2025-12-09

Swipe the table sideways to see every column.

Gelteq Ltd IPO

Gelteq Ltd filed a Form F-1 registration statement for an initial public offering on 2024-07-15. It has amended it 3 times. It filed its final prospectus on 2024-10-22. Each fact below is quoted from the filing named with it.

Our Ordinary Shares are listed on the Nasdaq Capital Market (“ Nasdaq ”) under the symbol “GELS.” On June 27, 2025, the closing price of our Ordinary Shares was $1.81 per share.From the F-1 filed 2025-07-01

We intend to use the net proceeds we receive from this offering as follows:From the 424B4 filed 2024-10-22

For the year ended June 30, 2023, the 60,000 units delivered in December 2022 has been recognized as revenue of AUD$79,843 (USD$51,898) from the deferred revenue balance at June 30, 2022.From the F-1 filed 2025-07-01

The Company is withdrawing the Registration Statement because the Company had not sold securities pursuant to the Registration Statement withdrawn hereby and expects to file a new registration statement for the offering.From the RW filed 2024-07-15

Swipe the table sideways to see every column.

Green Solar Energy Ltd IPO

Green Solar Energy Ltd filed a Form F-1 registration statement for an initial public offering on 2025-04-15. It has amended it 6 times. As of its latest filing, on 2025-11-25, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.

We have applied to list our Class A Shares on the Nasdaq Capital Market under the symbol “GLSA.” This offering is contingent upon the listing of our Class A Shares on the Nasdaq Capital Market.From the F-1/A filed 2025-11-25

This is an initial public offering of 3,750,000 Class A Shares, no par value, by Green Solar Energy Limited (“Green Solar” or “Company”), a British Virgin Islands business company limited by shares.From the F-1/A filed 2025-11-25

We intend to use the net proceeds from this offering for research and development, marketing and promotion campaigns, fix asset investment and working capital purposes.From the F-1/A filed 2025-11-25

For the years ended December 31, 2023 and 2024, our revenues were approximately AUD $5.9 million and AUD $5.2 million, respectively.From the F-1/A filed 2025-11-25

For the six months ended June 30, 2024 and 2025, we incurred net losses of AUD $234,385 and AUD $424,153, respectively, with an increase of net loss of AUD $189,768 or 81.0% as a result of decline in net revenues, decreases in gross margin of Sales of Systems and Power Storage Batteries, and increase in general and administrative expenses.From the F-1/A filed 2025-11-25

Swipe the table sideways to see every column.

Heartflow, Inc. IPO

Heartflow, Inc. filed a Form S-1 registration statement for an initial public offering on 2025-07-17. It has amended it 2 times. It filed its final prospectus on 2025-08-08, at a public offering price of $19.00 per share. Each fact below is quoted from the filing named with it.

Swipe the table sideways to see every column.

The newest 12 of 14 records.

Our common stock has been approved for listing on the Nasdaq Global Select Market under the trading symbol “HTFL.”From the 424B4 filed 2025-08-08

This is an initial public offering of shares of common stock of Heartflow, Inc. We are offering 16,666,667 shares of our common stock to be sold in this offering.From the 424B4 filed 2025-08-08

The initial public offering price is $19.00 per share.From the 424B4 filed 2025-08-08

We recognized revenue of $125.8 million for the year ended December 31, 2024, compared to revenue of $87.2 million for the year ended December 31, 2023, representing 44% year-over-year growth.From the S-1/A filed 2025-08-06

Our net losses were $95.7 million and $96.4 million for the years ended December 31, 2023 and 2024, respectively.From the S-1/A filed 2025-08-06

Swipe the table sideways to see every column.

Huachen AI Parking Management Technology Holding Co., Ltd IPO

Huachen AI Parking Management Technology Holding Co., Ltd filed a Form F-1 registration statement for an initial public offering on 2024-08-14. It has amended it 3 times. It filed its final prospectus on 2025-02-06, at a public offering price of $4.00 per share. Each fact below is quoted from the filing named with it.

Swipe the table sideways to see every column.

We have applied to list our Ordinary Shares on the Nasdaq Capital Market (“Nasdaq”) under the symbol “HCAI.” This Offering is conditioned upon the approval of listing of Nasdaq, and if it is not approved by Nasdaq, we will not proceed with this Offering.From the F-1/A filed 2025-01-23

Initial public offering price per share is $4.00 per share.From the 424B4 filed 2025-02-06

For the years ended December 31, 2023 and 2022, our revenues were approximately $34.28 million and $20.96 million, respectively.From the F-1/A filed 2025-01-23

Swipe the table sideways to see every column.

J-Star Holding Co., Ltd. IPO

J-Star Holding Co., Ltd. filed a Form F-1 registration statement for an initial public offering on 2025-04-29. It has amended it 7 times. It filed its final prospectus on 2025-07-31, at a public offering price of $4.00 per share. Each fact below is quoted from the filing named with it.

Our ordinary shares have been approved for listing on the Nasdaq Capital Market, or Nasdaq, under the symbol “ YMAT .”From the 424B4 filed 2025-07-31

The initial public offering price is $4.00 per share.From the 424B4 filed 2025-07-31

We plan to use the net proceeds of this offering as follows:From the 424B4 filed 2025-07-31

We had a net income of approximately $1.1 million and $1.4 million for the fiscal year ended December 31, 2024 and 2023, respectively.From the F-1/A filed 2025-05-16

Pursuant to Rule 477 under the Securities Act, the Company hereby requests that the Commission consent to the withdrawal of the Registration Statement, effective as of the date hereof.From the RW filed 2025-04-29

Swipe the table sideways to see every column.

Jyong Biotech Ltd. IPO

Jyong Biotech Ltd. has a Form F-1 registration statement on file for an initial public offering; the original was filed before the period this page covers, and the earliest filing here is an amendment filed on 2024-08-02. Amendments on record here: 8. It filed its final prospectus on 2025-06-18, at a public offering price of $7.50 per share. Each fact below is quoted from the filing named with it.

Swipe the table sideways to see every column.

Our ordinary shares have been approved for listing on the Nasdaq Global Market under the symbol “MENS.”From the 424B4 filed 2025-06-18

This is an initial public offering of 2,666,667 ordinary shares of Jyong Biotech Ltd., par value US$0.00001 per share, by Jyong Biotech Ltd. The initial public offering price of our ordinary shares is US$7.50 per share.From the 424B4 filed 2025-06-18

The initial public offering price is $7.50 per ordinary share.From the 424B4 filed 2025-06-18

We intend to use the net proceeds of this initial public offering to fund our future operations and debt obligations.From the 424B4 filed 2025-06-18

Swipe the table sideways to see every column.

K-Tech Solutions Co Ltd IPO

K-Tech Solutions Co Ltd filed a Form F-1 registration statement for an initial public offering on 2025-05-19. It has amended it 4 times. It filed its final prospectus on 2025-07-16. Each fact below is quoted from the filing named with it.

Swipe the table sideways to see every column.

Our ordinary shares are listed on The Nasdaq Capital Market under the symbol “KMRK.”From the F-1 filed 2025-09-15

We are offering 1,600,000 Class A Shares of the Company, on a firm commitment basis.From the 424B4 filed 2025-07-16

We intend to use the net proceeds from the IPO as follows:From the 424B4 filed 2025-07-16

For the years ended March 31, 2025 and 2024, our total revenue was US$18,612,534 and US$17,123,778, respectively.From the F-1 filed 2025-09-15

Swipe the table sideways to see every column.

Kairos Pharma, LTD. IPO

Kairos Pharma, LTD. filed a Form S-1 registration statement for an initial public offering on 2025-01-29. It has amended it 1 time. It filed its final prospectus on 2024-09-17, at a public offering price of $4.00 per share. Each fact below is quoted from the filing named with it.

Our common stock is listed on NYSE American under the symbol “KAPA.” On April 18, 2025, the last reported sale price of our common stock was $0.96 per share.From the S-1 filed 2025-04-22

This is a firm commitment initial public offering of shares of common stock, par value $0.001 per share, of Kairos Pharma, Ltd. We are offering 1,550,000 shares of our common stock at an initial public offering price of $4.00 per share.From the 424B4 filed 2024-09-17

This is a firm commitment initial public offering of shares of common stock, par value $0.001 per share, of Kairos Pharma, Ltd. We are offering 1,550,000 shares of our common stock at an initial public offering price of $4.00 per share.From the 424B4 filed 2024-09-17

We intend to use the net proceeds obtained under the ELOC Agreement to fund Phase 1 and Phase 2 clinical trials of our product candidates, including ENV 105 and preclinical product candidates including KROS 101, potential acquisition or in-licensing activities, and working capital and general corporate purposes.From the S-1 filed 2025-04-22

Swipe the table sideways to see every column.

Kandal M Venture Ltd IPO

Kandal M Venture Ltd filed a Form F-1 registration statement for an initial public offering on 2024-10-23. It has amended it 5 times. It filed its final prospectus on 2025-06-25, at a public offering price of $4.00 per share. Each fact below is quoted from the filing named with it.

Swipe the table sideways to see every column.

Our Class A Ordinary Shares have been approved for listing on the Nasdaq Capital Market, or Nasdaq, under the symbol “FMFC”.From the 424B4 filed 2025-06-25

We and the Selling Shareholders are offering 2,100,000 and 656,250 Class A Ordinary Shares of KMV, representing approximately 11.60% and 3.63% of the issued and outstanding ordinary shares, par value US$0.00001 per share, respectively, of KMV following completion of this offering and the sale of our Class A Ordinary Shares by the Resale Shareholder pursuant to the Resale Prospectus, assuming the underwriters do not exercise their over -allotment option.From the F-1/A filed 2025-01-16

(3) Based on the initial public offering price of $4 per Share shown on the cover page of this prospectus.From the 424B4 filed 2025-06-25

We plan to use the net proceeds of this offering as follows:From the 424B4 filed 2025-06-25

Swipe the table sideways to see every column.

Luda Technology Group Ltd IPO

Luda Technology Group Ltd filed a Form F-1 registration statement for an initial public offering on 2024-12-06. It has amended it 7 times. It filed its final prospectus on 2025-02-27. Each fact below is quoted from the filing named with it.

Our Ordinary Shares has been approved for listing under the symbol We have applied to list our Shares on the NYSE American under the symbol “LUD” on NYSE American LLC.From the 424B4 filed 2025-02-27

We are offering 2,500,000 Shares of Luda Cayman, on a firm commitment basis.From the 424B4 filed 2025-02-27

We intend to use the net proceeds from this offering as follows:From the 424B4 filed 2025-02-27

Pursuant to Rule 477 under the Securities Act, the Company hereby requests that the Commission consent to the withdrawal of the Registration Statement, effective as of the date hereof.From the RW filed 2024-12-06

Swipe the table sideways to see every column.

Maverick Lifestyle Inc. IPO

Maverick Lifestyle Inc. has a Form S-1 registration statement on file for an initial public offering; the original was filed before the period this page covers, and the earliest filing here is an amendment filed on 2024-10-07. Amendments on record here: 5. As of its latest filing, on 2025-01-28, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.

We have applied to list our Class A Common Stock on the NASDAQ Capital Market under the symbol “MVRK”.From the S-1/A filed 2025-01-28

We expect the initial public offering price to be between $5.50 and $6.50 per share.From the S-1/A filed 2025-01-28

We plan to use the net proceeds of this offering for marketing and advertising, hiring key personnel, machine upgrades, general working capital and other corporate purposes.From the S-1/A filed 2025-01-28

the last day of the fiscal year during which we have total annual gross revenues of $1.07 billion or more;From the S-1/A filed 2025-01-28

In addition, we have incurred significant net losses since our inception, with net losses of $1.8 million for the year ended December 31, 2023.From the S-1/A filed 2025-01-28

Swipe the table sideways to see every column.

MaxsMaking Inc. IPO

MaxsMaking Inc. filed a Form F-1 registration statement for an initial public offering on 2024-11-14. It has amended it 4 times. It filed its final prospectus on 2025-07-08, at a public offering price of $4.00 per share. Each fact below is quoted from the filing named with it.

We have been approved to list our A Shares listed on The Nasdaq Capital Market (“Nasdaq”) under the symbol “MAMK.”From the 424B4 filed 2025-07-08

We are offering 1,625,000 A Shares at an initial public offering price of $4.00 per share.From the 424B4 filed 2025-07-08

Swipe the table sideways to see every column.

Mibee Aviation Technology Holding Inc IPO

Mibee Aviation Technology Holding Inc filed a Form F-1 registration statement for an initial public offering on 2025-08-12. As of its latest filing, on 2025-08-12, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.

We intend to apply to list our common stock on the Nasdaq Capital Market under the symbol “ MFHK ”.From the F-1 filed 2025-08-12

Net loss for the year ended December 31, 2024, totaled $2,383,462 compared to $1,171,777 for the year ended December 31, 2023, resulting in an increase of $1,211,685 or 103%.From the F-1 filed 2025-08-12

Swipe the table sideways to see every column.

Moove Lubricants Holdings IPO

Moove Lubricants Holdings filed a Form F-1 registration statement for an initial public offering on 2024-09-16. It has amended it 1 time. It asked for the registration statement to be withdrawn on 2025-08-01. Each fact below is quoted from the filing named with it.

We have applied to list our common shares on the New York Stock Exchange under the symbol “MOOV.”From the F-1/A filed 2024-10-01

We intend to use the net proceeds from this offering for general corporate purposes, including working capital.From the F-1 filed 2024-09-16

(ii) fines of up to 2% of the revenue of the group’s last fiscal year, excluding taxes, up to an overall amount of R$50 million per violation;From the F-1/A filed 2024-10-01

Moove Lubricants Holdings (the “ Company ”) respectfully requests, pursuant to Rule 477(a) under the Securities Act of 1933, as amended (the “ Act ”), the immediate withdrawal of its Registration Statement on Form F-1 (File No. 333-282154), initially filed with the Securities and Exchange Commission (the “ Commission ”) on September 16, 2024, together with all exhibits and amendments thereto (collectively, the “ Registration Statement ”).From the RW filed 2025-08-01

Swipe the table sideways to see every column.

NuCana plc IPO

NuCana plc filed a Form F-1 registration statement for an initial public offering on 2025-04-24. It has amended it 2 times. It filed its final prospectus on 2025-05-07. Each fact below is quoted from the filing named with it.

Swipe the table sideways to see every column.

Our ADSs are listed for trading on The Nasdaq Capital Market under the symbol “NCNA”.From the 424B4 filed 2025-05-07

Because a purchaser’s purchase of ADSs in this offering could otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or at the election of the purchaser, 9.99%) of our outstanding ADSs immediately following consummation of this offering, we are offering to the purchasers pre-funded warrants to purchase up to 8,393,050 ADSs, or the Pre-Funded Warrants, in lieu of ADSs.From the 424B4 filed 2025-05-07

We intend to use the net proceeds of this offering, together with our existing cash and cash equivalents, to fund activities relating to the advancement of our drug discovery and development programs, and for other general corporate purposes, including, but not limited to, working capital, capital expenditures, investments, acquisitions, should we choose to pursue any, and collaborations See “Use of Proceeds” in this prospectus.From the 424B4 filed 2025-05-07

Swipe the table sideways to see every column.

OMS Energy Technologies Inc. IPO

OMS Energy Technologies Inc. filed a Form F-1 registration statement for an initial public offering on 2024-11-04. It has amended it 10 times. It filed its final prospectus on 2025-05-14. Each fact below is quoted from the filing named with it.

We have received the approval letter from the Nasdaq Stock Market LLC (“Nasdaq”) to list our Ordinary Shares on the Nasdaq Capital Market under the symbol “OMSE”.From the 424B4 filed 2025-05-14

We are offering, on a firm commitment basis, 3,703,704 Ordinary Shares.From the 424B4 filed 2025-05-14

We currently intend to use the net proceeds from this offering for (i) product research and development, (ii) marketing and sales, (iii) compliance and governance, and (iv) working capital.From the 424B4 filed 2025-05-14

Our revenue was $18.2 million for the period from April 1, 2023 through June 15, 2023 (Predecessor), $40.2 million for the period from June 16, 2023 through September 30, 2023 (Successor), and $129.2 million for the six months ended September 30, 2024 (Successor).From the F-1/A filed 2025-03-26

Swipe the table sideways to see every column.

Pitanium Ltd IPO

Pitanium Ltd filed a Form F-1 registration statement for an initial public offering on 2025-02-14. It has amended it 2 times. It filed its final prospectus on 2025-05-30, at a public offering price of $4.00 per share. Each fact below is quoted from the filing named with it.

Pitanium Limited has received approval from the Nasdaq Capital Market to list our Class A Ordinary Shares under the symbol “PTNM”.From the 424B4 filed 2025-05-30

We are offering 1,750,000 Class A Ordinary Shares, representing 8.86% of the Class A Ordinary Shares issued and outstanding following completion of the Offering, assuming the underwriter do not exercise the over-allotment option.From the 424B4 filed 2025-05-30

The initial public offering price is $4.00 per Class A Ordinary Share.From the 424B4 filed 2025-05-30

Our Operating Subsidiary’s revenue increased by HK$6,733,511 (approximately US$861,7 35 ) or 9.87% from HK$68,196,877 for the year ended September 30, 2023 to HK$74,930,388 (approximately US$9,589,371) for the year ended September 30, 2024.From the F-1/A filed 2025-05-07

As a result of the foregoing, our net income decreased by HK$1,359,125 (approximately US$173,939) or 13.25%, from HK$10,255,420 for the year ended September 30, 2023 to HK$8,896,295 (approximately US$1,138,521) for the year ended September 30, 2024.From the F-1/A filed 2025-05-07

Swipe the table sideways to see every column.

Qinhui Technology International Co. Ltd. IPO

Qinhui Technology International Co. Ltd. filed a Form F-1 registration statement for an initial public offering on 2025-02-11. It has amended it 4 times. As of its latest filing, on 2025-04-02, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.

We have reserved the symbol “QHT” for purposes of listing our ordinary shares on the Nasdaq Stock Market under the symbol “QHT”.From the F-1/A filed 2025-04-02

We plan to use the net proceeds of this offering as follows:From the F-1/A filed 2025-04-02

Our revenue was approximately US$19.7 million and we incurred a net loss in the amount of approximately US$2.9 million in the year ended December 2022.From the F-1/A filed 2025-04-02

Our revenue was approximately US$19.7 million and we incurred a net loss in the amount of approximately US$2.9 million in the year ended December 2022.From the F-1/A filed 2025-04-02

Swipe the table sideways to see every column.

Revelation Biosciences, Inc. IPO

Revelation Biosciences, Inc. filed a Form S-1 registration statement for an initial public offering on 2025-05-20. It has amended it 1 time. As of its latest filing, on 2025-05-23, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.

Swipe the table sideways to see every column.

Our common stock and warrants sold in our initial public offering (“Public Warrants”) are listed on The Nasdaq Stock Market, LLC (“Nasdaq”) under the ticker symbol “REVB” and “REVBW,” respectively.From the S-1/A filed 2025-05-23

We currently intend to use the net proceeds we receive from this offering to further the development of our Product Candidates including the (i) the completion of our ongoing Phase 1b clinical study, (ii) the manufacture of clinical drug supply, (iii) additional preclinical work for multiple indications, (iv) continue to develop other products and therapies, and (v) fund working capital and general corporate purposes using any remaining amounts.From the S-1/A filed 2025-05-23

We have incurred recurring losses since our inception, including a net loss of $15.0 million for the year ended December 31, 2024 and $0.1 million for the year ended December 31, 2023, respectively and a net of loss $2.1 million for the three months ended March 31, 2025 and $2.7 million for the three months ended March 31, 2024, respectively.From the S-1/A filed 2025-05-23

Swipe the table sideways to see every column.

Riverstone Ltd IPO

Riverstone Ltd filed a Form F-1 registration statement for an initial public offering on 2025-12-29. As of its latest filing, on 2025-12-29, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.

We have applied to list our Ordinary Shares on the Nasdaq Capital Market under the symbol “DNJF”.From the F-1 filed 2025-12-29

We currently intend to use the net proceeds from this offering as follows:From the F-1 filed 2025-12-29

Swipe the table sideways to see every column.

SHENNI HOLDINGS Ltd IPO

SHENNI HOLDINGS Ltd filed a Form F-1 registration statement for an initial public offering on 2025-03-14. It has amended it 1 time. It asked for the registration statement to be withdrawn on 2025-05-02. Each fact below is quoted from the filing named with it.

We have reserved the trading symbol SNI for listing on the NASDAQ.From the F-1/A filed 2025-03-31

We are offering on a firm commitment basis 3,000,000 ordinary shares.From the F-1/A filed 2025-03-31

We currently estimate that the initial public offering price will be between $4.00 and $6.00 per Ordinary Share.From the F-1/A filed 2025-03-31

We intend to use the net proceeds of this offering:From the F-1/A filed 2025-03-31

During the fiscal year ended March 31, 2024, our revenue increased by approximately 1618.7%, to approximately $10.58 million from $0.62 million for the fiscal year ended March 31, 2023.From the F-1/A filed 2025-03-31

In the fiscal year ended March 31, 2024, our net income amounted to approximately $1.54 million, representing an increase of approximately 1377.2%, compared to net loss of $0.12 million in the fiscal year ended March 31, 2023.From the F-1/A filed 2025-03-31

Pursuant to Rule 477 under the Securities Act of 1933, as amended (the “ Securities Act ”), Shenni Holdings Ltd., a foreign private issuer organized under the laws of Cayman Islands (the “ Company ”), hereby respectfully requests that the Securities and Exchange Commission (the “ Commission ”) consent to the withdrawal of its Registration Statement on Form F-1 (File No. 333- 285809) together with all exhibits thereto (the “ Registration Statement ”), effective as of the date hereof or at the earliest practicable date hereafter.From the RW filed 2025-05-02

Swipe the table sideways to see every column.

Sionna Therapeutics, Inc. IPO

Sionna Therapeutics, Inc. filed a Form S-1 registration statement for an initial public offering on 2025-01-17. It has amended it 1 time. It filed its final prospectus on 2025-02-07, at a public offering price of $18.00 per share. Each fact below is quoted from the filing named with it.

Layoffs on record: 1 filing or notice, latest 2026-09-14 (layoff filings and notices).

Swipe the table sideways to see every column.

Our common stock has been approved for listing on The Nasdaq Global Market (“Nasdaq”) under the symbol “SION.”From the 424B4 filed 2025-02-07

This is the initial public offering of shares of common stock of Sionna Therapeutics, Inc. We are offering 10,588,233 shares of our common stock.From the 424B4 filed 2025-02-07

The initial public offering price per share is $18.00.From the 424B4 filed 2025-02-07

We currently intend to use the net proceeds from this offering, together with our existing cash, cash equivalents and investments in marketable securities, (i) to complete our ongoing Phase 1 clinical trials, our planned Phase 2a proof of concept trial, and certain preclinical and other early clinical activities to enable potential advancement of our selected dual combination of an NBD1 stabilizer and complementary modulator;From the 424B4 filed 2025-02-07

Our net losses were $47.3 million and $40.2 million for the years ended December 31, 2023 and 2022, respectively.From the S-1/A filed 2025-02-03

Swipe the table sideways to see every column.

Smithfield Foods Inc IPO

Smithfield Foods Inc filed a Form S-1 registration statement for an initial public offering on 2025-01-06. It has amended it 1 time. It filed its final prospectus on 2025-09-05. Each fact below is quoted from the filing named with it.

Our common stock is listed on the Nasdaq Global Select Market under the symbol “SFD.” On September 4 , 2025, the last reported sales price of our common stock on the Nasdaq Global Select Market was $ 24.24 per share.From the 424B4 filed 2025-09-05

This is the initial public offering of common stock of Smithfield Foods, Inc. We are offering 13,043,479 shares of our common stock, and SFDS UK Holdings Limited (the “selling shareholder”), an indirect wholly owned subsidiary of our parent company, WH Group Limited (“WH Group”), is offering 13,043,479 shares of our common stock.From the 424B4 filed 2025-01-29

We expect that the initial public offering price of our common stock will be between $23.00 and $27.00 per share.From the S-1/A filed 2025-01-21

We intend to use the net proceeds to us from this offering for general corporate purposes, including capital investments in infrastructure, automation and capacity expansion.From the 424B4 filed 2025-01-29

For the three months ended December 29, 2024, we estimate that our net income from continuing operations will range from $195 million to $223 million, as compared to a net loss from continuing operations of $131 million for the three months ended December 31, 2023.From the S-1/A filed 2025-01-21

Swipe the table sideways to see every column.

Terra H Inc IPO

Terra H Inc filed a Form S-1 registration statement for an initial public offering on 2025-11-10. As of its latest filing, on 2025-11-10, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.

We have applied to list our common stocks on the Nasdaq Capital Market under the symbol “CYCE”.From the S-1 filed 2025-11-10

We are offering 1,000,000 ordinary shares of the Company pursuant to this Offering.From the S-1 filed 2025-11-10

Swipe the table sideways to see every column.

Top Create Biotech Co., Ltd. IPO

Top Create Biotech Co., Ltd. filed a Form F-1 registration statement for an initial public offering on 2025-07-02. As of its latest filing, on 2025-07-02, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.

We have applied to list our ordinary shares on the Nasdaq Capital Market under the symbol “TCBG”.From the F-1 filed 2025-07-02

Swipe the table sideways to see every column.

WF Holding Ltd IPO

WF Holding Ltd filed a Form F-1 registration statement for an initial public offering on 2024-09-23. It has amended it 5 times. It filed its final prospectus on 2025-03-28, at a public offering price of $4.00 per share. Each fact below is quoted from the filing named with it.

Swipe the table sideways to see every column.

In connection with this offering, we received approval to list our ordinary shares on The Nasdaq Capital Market under the symbol “WFF.” Our ordinary shares will commence trading on March 27, 2025.From the 424B4 filed 2025-03-28

We are offering 2,000,000 ordinary shares at an initial public offering price of $4.00 per share.From the 424B4 filed 2025-03-28

We are offering 2,000,000 ordinary shares at an initial public offering price of $4.00 per share.From the 424B4 filed 2025-03-28

We intend to use the net proceeds from this offering to expand our production capacity, to hire and train additional workers, and for working capital and general corporate purposes .From the 424B4 filed 2025-03-28

Our revenue decreased by $77,487, or 3.61%, to $2,067,101 for the six months ended June 30, 2024 from $2,144,588 for the six months ended June 30, 2023.From the F-1/A filed 2025-02-11

As a result of the cumulative effect of the factors described above, our net income was $ 218,705 for the six months ended June 30, 2024, as compared to $223,046 for the six months ended June 30, 2023, a decrease of $4,341, or 1.95%.From the F-1/A filed 2025-02-11

Swipe the table sideways to see every column.

Zhengye Biotechnology Holding Ltd IPO

Zhengye Biotechnology Holding Ltd has a Form F-1 registration statement on file for an initial public offering; the original was filed before the period this page covers, and the earliest filing here is an amendment filed on 2024-08-22. Amendments on record here: 2. It filed its final prospectus on 2025-01-07, at a public offering price of $4.00 per share. Each fact below is quoted from the filing named with it.

The initial public offering price is $4.00 per Ordinary Share.From the 424B4 filed 2025-01-07

For the fiscal years ended December 31, 2023 and 2022, our revenue was RMB211.7 million ($29.8 million) and RMB260.3 million ($36.7 million), respectively.From the F-1/A filed 2024-09-18

Swipe the table sideways to see every column.